DrugPatentWatch Database Preview

Details for Patent: 9,034,908

Which drugs does patent 9,034,908 protect, and when does it expire?

Patent 9,034,908 protects BENDEKA and is included in one NDA.

This patent has thirteen patent family members in five countries.

Summary for Patent: 9,034,908

Title:	Formulations of bendamustine
Abstract:	Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
Inventor(s):	Sundaram; Srikanth (Somerset, NJ)
Assignee:	EAGLE PHARMACEUTICALS, INC. (Woodcliff Lake, NJ)
Application Number:	13/838,090
Patent Claim Types: see list of patent claims	Use; Composition; Delivery;

Drugs Protected by US Patent 9,034,908

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;IV (INFUSION)	208194-001	Dec 7, 2015		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 9,034,908

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,572,887	Formulations of bendamustine	➤ Sign Up
9,572,888	Formulations of bendamustine	➤ Sign Up
9,579,384	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration	➤ Sign Up
9,000,021	Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents Family Members for US Patent 9,034,908

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2867295	➤ Sign Up
Canada	2867343	➤ Sign Up
China	104271135	➤ Sign Up
China	104302291	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 9,034,908

For more information try a trial or see the plans and pricing